Investigation of critical factors for the resolution of SR695, a key impurity, from efavirenz in the reversed-phase assay of efavirenz dosage forms

Journal of Pharmaceutical and Biomedical Analysis

Volumn 28, Issue 1, 2002, Pages 45-56

  Weissburg, Robert P ^a   Montgomery, Eda Ross ^a   Junnier, Lisa A ^a   Segretario, Jim ^a   Cook, Stacy ^a   Hovsepian, Paul K ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Cyano column; Efavirenz; Experimental design; Mixing volume; Resolution; Reversed phase chromatography; Sample solvent strength; Separation of double and triple bond homologs

Indexed keywords

DRUG; EFAVIRENZ; SR 695; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; DRUG CAPSULE; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG IMPURITY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TEMPERATURE; VALIDATION PROCESS;

CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSAGE FORMS; DRUG CONTAMINATION; DRUG EVALUATION, PRECLINICAL; OXAZINES; PHARMACEUTICAL SOLUTIONS; REVERSE TRANSCRIPTASE INHIBITORS; TEMPERATURE;

EID: 0036533167     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(01)00638-0     Document Type: Article

References (8)